Kyverna Therapeutics (KYTX) Capital Leases (2023 - 2025)
Kyverna Therapeutics posted quarterly Capital Leases of $8000.0 for Q3 2025, down 96.62% year-on-year from $237000.0 in Q3 2024, and down 69.23% on a QoQ basis from $26000.0 in Q2 2025.
Kyverna Therapeutics (KYTX) has 3 years of Capital Leases data on file, last reported at $8000.0 in Q3 2025.
- For the quarter ending Q3 2025, Capital Leases fell 96.62% year-over-year to $8000.0; the trailing twelve-month figure through Sep 2025 stood at $8000.0 (down 96.62% YoY), and the FY2024 full-year result was $142000.0, down 84.58% from the prior year.
- Capital Leases for Q3 2025 stood at $8000.0, down from $26000.0 in the prior quarter.
- Across five years, Capital Leases topped out at $921000.0 in Q4 2023 and bottomed at $8000.0 in Q3 2025.
- The 3-year median for Capital Leases is $189500.0 (2024), against an average of $310125.0.
- The widest annual swing landed in 2024, when Capital Leases slumped 84.58%; it then plunged 96.62% in 2025.
- A 3-year view of Capital Leases shows it stood at $921000.0 in 2023, then slumped by 84.58% to $142000.0 in 2024, then slumped by 94.37% to $8000.0 in 2025.
- The last three Capital Leases figures came in at $8000.0 (Q3 2025), $26000.0 (Q2 2025), and $73000.0 (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Kyverna Therapeutics | 497.98 Mn | 265.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 8,000.00 |
| Jun 30, 2025 | 26,000.00 |
| Mar 31, 2025 | 73,000.00 |
| Dec 31, 2024 | 142,000.00 |
| Sep 30, 2024 | 237,000.00 |
| Jun 30, 2024 | 407,000.00 |
| Mar 31, 2024 | 667,000.00 |
| Dec 31, 2023 | 921,000.00 |